4.7 Article

Improving sensitivity of magnetic resonance imaging by using a dual-targeted magnetic iron oxide nanoprobe

Journal

COLLOIDS AND SURFACES B-BIOINTERFACES
Volume 161, Issue -, Pages 339-346

Publisher

ELSEVIER
DOI: 10.1016/j.colsurfb.2017.10.059

Keywords

Fe3O4 magnetic nanoparticles; Bispecific nanoprobe; Magnetic resonance molecular imaging; Sensitivity

Funding

  1. National Key Research and Development Program of China [2017YFA0205502]
  2. National Basic Research Program of China (973 program) [2013CB733800]
  3. National Natural Science Foundation of China [81571806, 81671820, 81301870]
  4. Jiangsu Provincial Special Program of Medical Science [BL2013029]
  5. Fundamental Research Funds for the Central Universities

Ask authors/readers for more resources

Developing an ultrasensitive and high-efficient molecular imaging probe for detection of malignant tumors is extremely needed in clinical and remains a big challenge. Here, we report a novel bispecific nanoprobe for dual-targeted T2-weighed magnetic resonance imaging (MRI) of COLO-205 colorectal cancer in vivo. First, the magnetic iron oxide nanoparticles (Fe3O4@OA) were synthesized by a thermal decomposition method. Then, PEGylation of the hydrophobic Fe3O4@0A was implemented by amphiphilic DSPE-PEG2000-COOH, producing water-soluble nanoparticles (Fe3O4@PEG). Lastly, arginine-glycine-asparticacid-tumornecrosis factor-related apoptosis-inducing ligand (RGD-TRAIL), a bispecific fusion protein, was conjugated with the nanoparticle to construct molecularly multi-targeted nanoprobe, which was defined as Fe3O4@RGD-TRAIL. This Fe3O4@RGD-TRAIL was proven to exhibit extremely high relaxation property (r(2) = 534 mM(-1) s(-1)) and saturation magnetization value (M-s = 92 emu/g Fe). In vitro studies showed its dual-targeting combination capacity, favorable biocompatibility and strong ability to resist against the non-specific phagocytosis. Owing to these excellent advantages, high sensitive and efficient imaging of tumor was achieved in vivo. Therefore, this RGD-TRAIL conjugated nanoprobe could be developed as a multi-targeted contrast enhancement agent for magnetic resonance molecular imaging in detection of cancer. (C) 2017 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available